Review

Exosomes in osteoarthritis and cartilage injury: advanced development and potential therapeutic strategies

Quanfa Zhou¹, Youzhi Cai¹,², Yangzi Jiang³ and Xiangjin Lin¹

¹. Department of Orthopaedic and Center for Sports Medicine, the First Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, Hangzhou, China
². Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Regenerative Medicine, School of Medicine, Zhejiang University, Hangzhou, China.
³. Institute for Tissue Engineering and Regenerative Medicine, School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong S.A.R., China

Corresponding author: Youzhi Cai, M.D., Orthopaedic Department and Sports Medical Center, First Affiliated Hospital of Zhejiang University, Building for 79 Qingchun Road, Shangcheng District, Hangzhou, China, 31003. Email: caiyouzhi@zju.edu.cn.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2019.11.03; Accepted: 2020.03.10; Published: 2020.03.31

Abstract

Articular cartilage injury is a common clinical problem, which can lead to joint dysfunction, significant pain, and secondary osteoarthritis (OA) in which major surgical procedures are mandatory for treatment. Exosomes, as endosome-derived membrane-bound vesicles, participating in intercellular communications in both physiological and pathophysiological conditions, have been attached great importance in many fields. Recently, the significance of exosomes in the development of OA has been gradually concerned, while the therapeutic value of exosomes in cartilage repair and OA treatment has also been gradually revealed. The functional difference of different types and derivations of exosomes are determined by their specific contents. Herein, we provide comprehensive understanding on exosome and OA, including how exosomes participating in OA, the therapeutic value of exosomes for cartilage injury/OA, and related bioengineering strategies for future therapeutic design.

Key words: exosome, osteoarthritis, cartilage, exosomal RNA, stem cells, cellular and exosomal therapies

Introduction

The occurrence of osteoarthritis (OA) implies an imbalance in degradation-synthesis of chondrocytes, extracellular matrix (ECM) and subchondral bone, but the detailed molecular mechanisms remain unclear. Exosomes, as a type of extracellular vesicles (EVs), play a role in tissue–tissue and cell–cell communications in homeostasis and diseases, and the mechanism of exosomal involvement in the development of OA has only recently been reported. Thus, understanding how exosomes participate in the process of OA will help to seek a novel way for developing the treatment of OA.

Traditional non-surgical treatments for OA can improve symptoms but cannot restore articular cartilage regeneration or modify degenerative processes [¹]. Although surgical arthroplasty results in long-term functional improvement and improves quality of life, this only suit for the end stage of the diseases, and instability and infection are the most common limitations, necessitating further revision surgery. Cell-based therapy, especially mesenchymal stem cells (MSCs), has facilitated rapid advances in regenerative medicine for OA/cartilage injury in recent years. However, the clinical applications of stem cells have raised considerable concerns, such as teratomas, immune rejection, non-stable between batches and dose-dependent effect [²-³]. The bio-effects of MSCs mainly through paracrine, especially via the exosomes they produced [⁴]. Thus, exosome-based therapy may be a promising substitute for stem cell therapy on cartilage injury/OA, which provides the possibility of “cell-free” therapy.

http://www.ijbs.com
This review will focus on the biological characteristics of exosomes, and the involvement of exosomes in pathology of OA will be discussed in detail. We will also discuss the evidence that shows how exosomes can be used as “cell-free” therapy for OA/cartilage injury, and the detailed exosome-based tissue engineering strategies. Finally, we will also discuss future development in this exciting field.

The biological characteristics of exosomes

Exosomes are endosome-derived membrane-bound vesicles with diameters of 50-150 nm, released by cells in all living systems in physiological and pathophysiologica conditions [5]. Exosomes originate from the endosomes that are generated by endocytosis of the cytoplasmic membrane. Later, inside the cell, cargoes such as mRNA or proteins accumulate inside the endosomes, thus forming multivesicular endosomes or intraluminal vesicles [6]. After further processing, exosomes are finally released through membrane fusion [7]. At early ages, exosomes were regarded as useless cellular metabolic waste, but it has since been recognized that exosomes carry proteins, lipids, and nucleic acids, including mRNA, microRNA (miRNA), and long non-coding RNA, which play important roles in intercellular communications and cellular immune response [8].

The biogenesis and release of exosomes is a complex symphony involving a series of factors, representatively including the endosomal sorting complexes required for transport (ESCRT), ALIX (also known as programed cell death 6-interacting protein, PDCD6IP), phospholipase, vacuolar protein sorting-associated 4 (VPS4), Rab GTPase proteins, sphingomyelinase and ceramide. Recently, the inhibition effect of exosome release was reported by sustained activation of mechanistic target of rapamycin complex 1 (mTORC1) in both cells and animal models, while inhibition of mTORC1 stimulated the release of exosomes, which occurred concomitantly with autophagy [9].

The recognition of membrane receptors is the basis for the exosome–cell reaction and interactions. The activation of the receptors and subsequently lead to the activation of associated signaling pathways, subsequently the fusion of exosomes with plasma membrane or the endocytosis of exosomes occurs. Through above-mentioned internalization pathways, exosomes can either release their cargos into the recipient cells to exert their functions, or be directly degraded by lysosome for recycling [10]. Thus, the function and biological characteristic of exosomes are determined by their specific contents.

Pathological related exosomes in OA

Although many beneficial biological effects are based on exosomes, in OA joint, chondrocytes, synoviocytes and immune cells may also deliver pathogenic signals to each other through exosomes, and these communications break the balance of joint microenvironment and further aggravate OA. In OA tissues, an increased number of immune cells associated with pro-inflammatory cytokine expression, including tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6 and IL-22, was detected from OA synovial tissue [11], while matrix metalloproteinase (MMP), is thought to be the major mediator of ECM breakdown, which causes the majority of the pathologies seen in OA [12]. Analysis the relationship between exosomes and these important pathological factors may provide insights for our understanding of OA pathology (Figure 1).

Exosomes in OA pathology

Exosomes in OA joint fluid were firstly analyzed by many research groups and it indeed usually links with pathological effects. Exosomes from OA joint fluid could influence the gene expression of chondrocytes negatively. Kolhe et al treated healthy articular chondrocytes with OA-derived exosomes, showing decreased anabolic genes expression and elevated expression of catabolic and inflammatory genes [13]. In addition, exosomes from OA joint fluid could activate inflammatory cells. Domenis et al found that synovial fluid-derived exosomes significantly stimulated the release of several inflammatory cytokines, chemokines and metalloproteinases by M1 macrophages [14]. Incubating macrophages with exosomes from synovial fluid of OA, Song et al demonstrated that the exosomes could induced proliferation and osteoclast formation without macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor kappa-B ligand (RANKL) [15].

Furthermore, some researches have studied the role of exosomes in the communication between chondrocytes and other cells in OA. Nakasa et al reported that when exosomes derived from chondrocytes treated with IL-1β were applied to fibroblast-like synoviocytes, there was a nearly three-fold increase in MMP-13 production as compared with exosomes derived from chondrocytes without IL-1β stimulation [16]. In turn, Kato et al found exosomes from IL-1β stimulated human synovial fibroblasts (SFB) up-regulated MMP-13 and ADAMTS-5 expression in articular chondrocytes and down-regulated collagen alpha 1 (Col2a1) and aggregated proteoglycan core protein (ACAN) in vivo [17]. In one chip-assay study, 50 miRNAs were
identified in exosomes in response to IL-1β-stimulated SFB compared to non-stimulated SFB, and among them, miR-4454 and miR-199b are related to inflammatory stimulation [18] and cartilage formation [19], respectively. Ni et al found the exosome-like vesicles from IL-1β-pretreated chondrocytes could promote mature IL-1β production of macrophages [20].

Kolhe et al reported the differential expression of miRNAs between exosomes from OA synovial fluid and normal synovial fluid [13]. They found the gender differences of the expression of exosomal miRNAs, with only one (miRNA-504) existing in both genders. Interestingly, the authors also demonstrated that female OA-specific exosomal-miRNAs from synovial fluid were estrogen-responsive and targeted toll-like receptor (TLR) signaling pathways, which might relate to the increased prevalence of OA in post-menopausal females. Furthermore, the patients with OA had lower levels of exosomal miR-193b in plasma than normal control subjects [21].

The differential expression of miRNA of exosomes from chondrocytes in the inflammatory microenvironment which related to OA has been reported recently. Exosomal miR-92a-3p expression was significantly reduced in the OA chondrocyte-secreted exosomes. Mao et al found that miR-92a-3p suppressed the activity of a reporter construct containing the 3'-UTR and directly targeted WNT5A in both MSCs and chondrocytes [22], and WNT5A plays important role in both chondrogenic differentiation and cartilage degradation [23]. Mao et al also found another exosomal miRNA (miR-95-5p) was down-regulated in OA chondrocytes [24]. Furthermore, they demonstrated that miR-95-5p could regulate cartilage development and homeoeostasis by directly targeting histone deacetylase (HDAC2/8). HDAC2/8 tends to impede cartilage development by inhibiting the expression of cartilage-specific genes [25].

Many exosomal miRNAs are found to be related to OA development, there are exosomal proteins related to OA too. Recently, Varela-Eirín et al found that overexpression of channel protein connexin43 (Cx43) in chondrocytes increased senescence and exosomal Cx43 levels [26]. In this study, OA chondrocytes showed increased levels of Cx43 within their EVs in comparison to the EVs isolated from healthy donors.

The Diagnostic Value of Exosomes for OA

Theoretically, the variation levels of exosomal miRNAs or proteins mentioned above have potential
to become biomarkers for OA diagnosis. However, the value of exosomes as a diagnostic tool of OA is still under discussion. Recently, Zhao et al. investigated the diagnostic value of exosomes from plasma and from synovial fluid in patients with OA in distinguishing the early stage of OA from progressive stage of OA [27]. They found that in synovial fluid, the expression of exosomal lncRNA PCGEM1 was markedly higher in late-stage OA than in early-stage OA, and markedly higher in early-stage OA than normal controls, demonstrating that exosomal lncRNA PCGEM1 from synovial fluid might be a powerful indicator in distinguishing early-stage from late-stage OA. lncRNA PCGEM1 acts as a sponge lncRNA targeting miR-770 and then stimulates proliferation of osteoarthritic synoviocytes [28]. However, the general evaluation of plasma and synovial fluid exosome was not viable for identifying OA stages, and the clinical application of exosomes in the diagnosis of OA remains challenging.

Exosomes with therapeutic effects for OA and cartilage injury

The exosomes from mesenchymal stem cells

Exosomes are one of the key secretory products of MSCs, resembling the effect of parental MSCs, and can be directly used as therapeutic agents for various disease models, such as cutaneous wound [29], osteonecrosis of the femoral head [30], and neurological injury [31]. Recent years, exosomes from different unmodified MSCs were reported to have exact therapeutic effects on OA and cartilage injury (Figure 2).

Exosomes from different types of MSCs

Cartilage regeneration from bone marrow mesenchymal stem cells (BMSCs) is the core of microfracture technology. Exosomes from BMSCs have been studied in recent years. Cosenza et al. demonstrated the protective effect of exosomes from BMSCs in the collagenase-induced OA model [32]. Furthermore, they found exosomes from BMSCs could restore the expression of chondrocyte markers (type II collagen, aggrecan) while inhibiting catabolic (MMP-13, ADAMTS5) and inflammatory (iNOS) markers in OA-like chondrocytes in vitro. Zhu et al. also revealed that BMSCs derived exosomes could protect chondrocytes from apoptosis and senescence [33]. Furthermore, Qi et al. observed the uptake of exosomes from BMSCs by chondrocytes [34], and exosomes from BMSCs could inhibit mitochondrial-induced apoptosis of chondrocytes in response to IL-1β, with p38, ERK, and Akt pathways involved.

---

**Figure 2.** Exosomes from unmodified cells for OA therapy/cartilage.
Exosomes from embryonic MSC (ESCs) have shown the potential of alleviating matrix degradation and promoting cartilage repair in some animal models [35-37]. Further in vitro, exosomes from ESCs could maintain the chondrocyte phenotype by increasing collagen type II synthesis and decreasing ADAMTS5 expression [34]. Zhang et al demonstrated that the joint repair effects of exosomes from ESCs could be attributed to adenosine activation of protein kinase B(AKT), extracellular signal-regulated kinase (ERK) and adenosine monophosphate-activated protein kinase (AMPK) signaling [37]. In addition, they also found that the joint repair effects might be related to exosomal CD73 expression which can convert extracellular AMP to adenosine, as well as exosomal transforming growth factor-β (TGF-β) and insulin growth factor (IGF).

Due to the feasibility to obtain human infrapatellar fat pad from OA patients by arthroscopy, using exosomes from adipose-derived mesenchymal stem cells (ADSCs) has gradually gain more attentions. Tofiño-Vian et al found exosomes from ADSCs could down-regulated senescence-associated β-galactosidase activity and the accumulation of γH2AX foci, and reduced the production of inflammatory mediators from OA osteoblasts [38]. They also reported that exosomes from ADSCs could reduce the production of inflammatory and catabolic mediators from OA chondrocytes stimulated with IL-1β [39]. The chondroprotection role could be the consequence of a lower activation of nuclear factor-kB and activator protein-1. In other study, Wu et al attributed the cartilage protection of exosomes from ASCs to the high level of exosomal miR-100-5p [40], because the exosomal miR-100-5p could bind to the 3′-untranslated region (3′UTR) of mTOR, then significantly enhance autophagy level in OA chondrocytes via mTOR inhibition.

**Therapeutic contents in exosomes**

It is significant to figure out the therapeutic contents in exosomes. Recently, Liu et al verified that IncRNA KLF3-AS1 in human MSCs and exosomes derived from human MSCs (MSC-Exos) by qRT-PCR analysis [41], and it might be the key molecule with therapeutic effect. In their study, treating rat chondrocytes with the MSC-Exos whose IncRNA KLF3-AS1 expression was knocked down could reverse the normal chondroprotection of MSC-Exos. The knee joint cartilage damage of rat OA model was also deteriorated by the MSC-Exos without IncRNA KLF3-AS1 expression. These data suggested that the therapeutic effect of MSC-Exos on OA is related to the newly discovered exosomal IncRNA KLF3-AS1.

**Comparison of the effects of exosomes**

More importantly, exosomes from different cell types may have different effects, and this topic is still under investigation. Zhu et al compared the effects of exosomes secreted by synovial membrane MSCs (SMMMSC-Exos) and exosomes secreted by induced pluripotent stem cell-derived MSCs (iMSC-Exos) in treating OA [42]. They found both exosomes attenuated OA in the mouse OA model, but iMSC-Exos had a superior therapeutic effect compares to SMMMSC derived exosomes, and iMSC-Exos exerted a stronger effect on chondrocyte migration and proliferation in vitro. In another study, Chen et al found that exosomes derived from chondrocytes (CC-Exos) increased collagen deposition and minimized vascular ingrowth in engineered constructs, and efficiently and reproducibly developed into cartilage, while the BMSC-Exos treated tissue engineered construct was characterized with hypertrophic differentiation accompanied by vascular ingrowth [43]. In vitro, CC-Exos could stimulate cartilage progenitor cells proliferation and significantly promoted chondrogenesis-related factors at the mRNA and protein levels.

**Exosomes from molecular engineered cells**

The strategies of utilizing exosome loading technology to obtain customized drug-loaded exosomes are gradually applied in the field of OA therapy (Figure 3). There are two ways to load drugs into exosomes, one is to load drugs into the donor cell of exosomes, such as using transfection and co-incubation; the other is to load drugs into exosomes after they are secreted, such as direct mixing, which the loading efficacy is a big concern. At present, most researchers prefer to obtain the exosomes for OA therapy with high expression of miRNA or IncRNA from modified MSCs [22,44-46]. Exosomal miR-92a-3p [23], exosomal IncRNA-KLF3-AS1 [44], exosomal miR-140-5p [45] and exosomal miR-320c [46] from transfected MSCs have been reported to have significant therapeutic effects on OA in vivo and in vitro. Furthermore, it was reported that primary chondrocytes also could be modified to serve as the donor cells of exosomes [24]. In that study, exosomes derived from miR-95-5p-overexpressing primary chondrocytes promoted cartilage development and cartilage matrix expression by directly targeting HDAC2/8 in MSCs induced to undergo chondrogenesis and chondrocytes, respectively. In addition to transfection, treating the donor cells with proper growth factors such as TGF β1 can also improve the productivity of therapeutic exosomes [47].
Figure 3. Exosomes from modified cells for OA therapy/cartilage repair.

Tissue engineering strategies for exosomes

Exosome-based tissue engineering technology representing an advanced strategy, has attracted increasing attention in many fields (Table 1). In this section, we will focus on some representative exosome-based tissue engineering strategies (Figure 4) and discuss their application potential in OA therapy/cartilage repair.

3D culture for exosome generation

In a multicellular organism, tissue cells are highly organized in a 3-dimensional (3D) fashion and are surrounded by the extracellular matrix (ECM) [48]. Under 2-dimensional (2D) conditions, cells lack the in vivo spatial polarization and architecture, leading to changes in cellular morphology, proliferation and functionalities, such as the processing and function of EVs [49]. Therefore, for better understanding the roles of exosomes in OA development and treatment, the technology of 3D culture, has attracted increasing attention in order to improve on the inadequate reproduction of the in vivo microenvironment by 2D culture.

Some studies have reported that exosome produced by 3D cultures (Exos/EVs-3D) has more advantages than exosome produced by 2D cultures (Exos/EVs-2D) [50-57] in terms of the size, content, function and production efficiency of exosomes. The functions of exosomes differ according to their content, while Exos/EVs-3D contain a different profile of proteins and genetic materials compared to Exos/EVs-2D [52]. The enhanced production efficiency of Exos/EVs-3D might relate to the reduction of expression of F-actin in 3D culture [53]. However, there is also one study reporting no difference in functions regarding the 2D/3D derivation of exosomes [54].

Table 1. Tissue Engineering Strategies for Osteoarthritis and Cartilage Injury

| Tissue-Engineering Technology | Advantages for exosomes | Related reports |
|-------------------------------|-------------------------|-----------------|
| 3D culture                    | Regulating the biological characteristics; | Size[50-51]; Content[50-52, 55-57]; Function[50, 52, 54-55]; Production efficiency[50, 52-53, 55-57] |
| Nanoparticles                 | Changing biological characteristics; | Regulating exosome release of parent cells [58,59]; Regulating content of exosome[60]; |
|                               | Surface modification; | Improving the targeting ability of exosomes[61]; |
|                               | Combining with exosomes for improving deficiencies; | Efficiently encapsulating large plasmids[62]; |
| 3D biomaterials               | Exosome retention and sustained release function as working platforms; | Bone regeneration[63]; Cardiac repair[65]; Vascular disease[66]; Wound healing[67]; Cartilage repair[71]; |
|                               | Increasing the stability of content; | Increasing the stability of proteins and miRNAs in exosomes[68]; |
| 3D printing                   | Designing more optimized 3D culture microenvironment; | Improving the productivity and functions of exosomes[57]; |
|                               | Designing scaffolds with more optimized geometric structure; | Bone defect repair[72]; Osteoangiogenesis[73]; Cartilage repair[74]; |
Nanoparticles

Nanoparticles can influence and assist the production and function of exosomes. Kasper et al. found silica nanoparticles could decrease secretion of ICAM/E-selectin bearing exosomes/microvesicles when exposed to the inflamed endothelium [58]. Roma-Rodrigues et al. found that gold nanoparticles (AuNPs) functionalized with thiolated oligonucleotides anti-RAB27A could decrease the release of exosomes due to specific gene silencing [59]. In addition, nanoparticles can also affect the sorting of exosomal cargos. Liang et al. demonstrated that Sphk2 gene silencing induced by siRNA loaded nanoparticles could reduce miRNA-21 sorting into exosomes [60]. Nanoparticles can also enhance the targeting ability of exosomes. Khongkow et al. reported that the surface modification of AuNPs with brain-targeted exosomes derived from genetically engineered mammalian cells enhanced their transport across the blood-brain-barrier [61]. Moreover, nanoparticles can also enhance the drug loading ability of exosomes. In order to solve the problem of low efficiency of exosomes in encapsulation of large nucleic acids, Lin et al. developed a kind of hybrid nanoparticle combining exosome and liposome via simple incubation, which efficiently encapsulates large plasmids [62].

3D biomaterials and exosome retention

3D scaffolds could be further used as working platforms for the exosomes while attempting to control the release of exosomes in the tissue repaired area [63-64]. Hydrogel has been widely used as 3D scaffold due to their unique features, such as high water content, biocompatibility, swelling behavior, and modulated 3D networks, in many restorative areas, such as cardiac repair [65], vascular disease [66], wound healing [67]. Recently, Zhang et al. reported that chitosan hydrogel could notably increase the stability of proteins and miRNAs in exosomes [68]. In OA therapy, hydrogel materials also have been widely used to better fill the cartilage defect and provide a mode and mechanical support for cartilage regeneration [69]. Interestingly, hydrogel materials have been proven to have good exosome retention and sustained release function. Schneider et al. found that many types of proteins secreted by chondrocytes encapsulated within photoclickable poly(ethylene glycol) hydrogels have been reported to be present within cell-secreted exosomes [70]. They suggested that the ability of diffusing through the hydrogel of smaller exosomes contributed to the results. Liu et al. exploited a photoinduced imine crosslinking hydrogel glue as an exosome scaffold to prepare an acellular tissue patch for cartilage regeneration [71]. They found that most of
the encapsulated exosomes were retained inside the hydrogel (>90%) after immersing in PBS for 14 days. In addition, the tissue patch could release low concentration of exosomes showing positive regulation to the surrounding cells.

3D bio-printing

3D printing has been well used in cartilage tissue repair, and to adopt the great bioeffects of exosome into 3D printing technology, there are two break points for further development. One is to improve the productivity and functions of exosomes by using optimized 3D culture microenvironment, which can be precisely designed and printed with 3D bio-printers [57]. The other is to design advanced bio-mimic scaffolds with more optimized geometric structure and better incorporate with exosomes, thus enhancing the therapeutic effects of exosomes or EVs [72-73]. For instance, Chen et al reported the interaction between 3D printing scaffold and exosome in cartilage repair [74]. They fabricated a 3D printed cartilage ECM/gelatin methacrylate/exosome scaffold with radially oriented channels using desktop-stereolithography technology. They found the 3D printed scaffold could effectively retain exosomes for 14 days in vitro and could retain exosomes for at least 7 days in vivo. They also found that the 3D printed scaffold could recruit chondrocytes, which was mainly attributed to ECM, and that exosomes could further enhance this effect.

Future perspective

Drug-loading techniques

The cell-friendly biological feature of exosome decides that the future drug application via exosome may provide a higher delivery efficiency. The recent research tend is to modify the exosome-secreting cells with transfection to load miRNA(s) into exosomes, thus can be used for OA therapy/cartilage repair [23,44-46]. However, the transfection method in loading RNA has many limitations, such as the unstable productivity of RNA and the unclear factors influencing the RNA level and loading [75], which means the application is still far from clinic. Other drug loading techniques applied for OA treatment/cartilage repair have not been reported yet, therefore it is significant to develop new drug loading technologies. One of the direction is to use nanoparticles, which could improve the drug loading capacity of exosomes [62]. All in all, to explore the cargo-loading mechanism of exosomes and search for more efficient and stable drug loading technology, will accelerate the development of exosome-based OA therapy/cartilage repair.

Local sustained release system

Most recent studies demonstrate that exosomes play a significant role in OA therapy/cartilage repair both in animal models and preclinical trials. Nevertheless, the current therapy requests repeatedly local administration for maintaining the effective concentration, which increase pain and the risk of side effects to the subjects. To solve this problem, local controlled release of exosomes with bio-scaffold has begun to be valued [74]. Controlled delivery of therapeutic agents on local joint lesion possesses two advantages. One is that controlling the degradation time of drug vehicle/bio-degradable scaffold and maintaining the effective concentration of drugs, thus prolonging the functional time of drugs at desired dosages. The other is that it will be helpful to combine the exosome-working-platform with other sustained drug release technologies according to the degrees of cartilage injury and osteoarthritis, which can be designed and become personalized therapeutics in the future.

Personalized and “point-to-point” treatment

Over the past few years, the arrival of liquid biopsy technology has made the generating a database of OA patients much easier, including information concerning exosomes. With the gradual understanding of the mechanism of exosome involved in OA and adequate information from the database, the patient’s articular condition can be analyzed individually. It would be possible to assemble the needed cargos and drugs into the modularized exosomes to achieve personalized treatment with maximizing the therapeutic effect. In addition, the key concept of precision medicine is to treat or “ablate” the pathological condition without damage to normal tissues. As a consequence, exosomes will be a poetical biomarker and therapeutic tool for personalized and precision treatment of OA therapy/cartilage repair in the future.

Conclusion

Exosomes derived from chondrocytes, synovial cells, and synovial fluid have been shown to be involved in the pathogenesis of OA. Meanwhile many studies have shown that exosomes from natural cells, especially MSCs, could maintain chondrocyte homeostasis and ameliorate the pathological severity of OA, demonstrating the potential therapeutic effect of exosomes for OA/cartilage injury. In addition, exosomes from modified cells with drug loading technologies have been shown improved therapeutic effect. Tissue engineering techniques are also used in the exosome-based OA therapy/cartilage repair. Biological scaffolds, especially hydrogel, have been
shown to have a good sustained exosome-release effect in cartilage repair. The 3D printing technology can be used to construct more reasonable 3D culture microenvironments for exosomes, and can contribute to design scaffolds with more optimized geometric structure. We believe that drug loading, sustained release and individualized treatment will be the main directions of exosome-based OA therapy/cartilage repair in the near future.

Acknowledgements

This work was supported by the National Key R&D Program of China (2019YFA0111900 to YJ), Key Scientific and Technological Innovation Group of Zhejiang Province (2013TD11 to HOY), Zhejiang Province grants (LY17H006003 to JP), NSFC grants (81201395 to YC), and the Dr. Li Dak Sum & Yip Yio Chin Development Fund for Regenerative Medicine.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Sinusas K. Osteoarthritis: diagnosis and treatment. Am Fam Physician. 2012;85(1):49-56.
2. Park S, Choi Y, Jung N, Yu Y, Ryu KH, Kim HS, et al. Myogenic differentiation potential of human tissuederived mesenchymal stem cells and their potential for use to promote skeletal muscle regeneration. Int J Mol Med. 2016; 37(5):1209-20.
3. Jo CH, Lee YG, Shin WH, Kim H, Chai JW, Jeong EC, et al. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. Stem Cells. 2014; 32(5): 1245-64.
4. Pashoutan Sarvar D, Shamsanekan J, Akbarzadehpaibol P. Mesenchymal Stem Cell-Derived Exosomes: New Opportunity in Cell-Free Therapy. Adv Pharm Bull. 2016;6(3):293-299.
5. Mathieu M, Martin-Iaulier L, Lavieu G, Théry C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol. 2019; 21(1): 9-17.
6. Adlavadi S, Wang X, Gu H, Fan GC. Pathologic function and therapeutic potential of exosomes in cardiovascular disease. Biochim Biophys Acta. 2015a; 1852(11):1-11.
7. Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014; 30: 235-60.
8. Kao CY, Papoutsakiti ET. Extracellular vesicles: exosomes, microparticles, their parts, and their targets to enable their biomanufacturing and clinical applications. Curr Opin Biotechnol. 2019; 62: 89-98.
9. Zou W, Lai M, Zhang Y, Zheng L, Xing Z, Li T, Zou S, Qiao X, Xiao L, Yang J, Liu A, Zhang HZ, Cui ZK, Jiang Y, Bai X. Exosome Release Is Regulated by mTORC1. Adv Sci (Weinh). 2018; 6(3): 1801313.
10. Zou W, Lai M, Zhang Y, Zheng L, Xing Z, Li T, Zou S, Qiao X, Xiao L, Yang J, Liu A, Zhang HZ, Cui ZK, Jiang Y, Bai X. Exosome Release Is Regulated by mTORC1. Adv Sci (Weinh). 2018; 6(3): 1801313.
11. Zou W, Lai M, Zhang Y, Zheng L, Xing Z, Li T, Zou S, Qiao X, Xiao L, Yang J, Liu A, Zhang HZ, Cui ZK, Jiang Y, Bai X. Exosome Release Is Regulated by mTORC1. Adv Sci (Weinh). 2018; 6(3): 1801313.
12. Zou W, Lai M, Zhang Y, Zheng L, Xing Z, Li T, Zou S, Qiao X, Xiao L, Yang J, Liu A, Zhang HZ, Cui ZK, Jiang Y, Bai X. Exosome Release Is Regulated by mTORC1. Adv Sci (Weinh). 2018; 6(3): 1801313.
13. Zou W, Lai M, Zhang Y, Zheng L, Xing Z, Li T, Zou S, Qiao X, Xiao L, Yang J, Liu A, Zhang HZ, Cui ZK, Jiang Y, Bai X. Exosome Release Is Regulated by mTORC1. Adv Sci (Weinh). 2018; 6(3): 1801313.
14. Zou W, Lai M, Zhang Y, Zheng L, Xing Z, Li T, Zou S, Qiao X, Xiao L, Yang J, Liu A, Zhang HZ, Cui ZK, Jiang Y, Bai X. Exosome Release Is Regulated by mTORC1. Adv Sci (Weinh). 2018; 6(3): 1801313.
15. Zou W, Lai M, Zhang Y, Zheng L, Xing Z, Li T, Zou S, Qiao X, Xiao L, Yang J, Liu A, Zhang HZ, Cui ZK, Jiang Y, Bai X. Exosome Release Is Regulated by mTORC1. Adv Sci (Weinh). 2018; 6(3): 1801313.
16. Zou W, Lai M, Zhang Y, Zheng L, Xing Z, Li T, Zou S, Qiao X, Xiao L, Yang J, Liu A, Zhang HZ, Cui ZK, Jiang Y, Bai X. Exosome Release Is Regulated by mTORC1. Adv Sci (Weinh). 2018; 6(3): 1801313.
17. Zou W, Lai M, Zhang Y, Zheng L, Xing Z, Li T, Zou S, Qiao X, Xiao L, Yang J, Liu A, Zhang HZ, Cui ZK, Jiang Y, Bai X. Exosome Release Is Regulated by mTORC1. Adv Sci (Weinh). 2018; 6(3): 1801313.
Int. J. Biol. Sci. 2020, Vol. 16

50. Wu J, Kuang L, Chen C, Yang J, Zeng WN, Li T, Chen H, Huang S, Fu Z, Li J, Liu R, Ni Z, Chen L, Yang L. miR-100-5p-abundant exosomes derived from infrapatellar fat pad MSCs protect articular cartilage and ameliorate gait abnormalities via inhibition of mTOR in osteoarthritis. Biomaterials. 2019; 206:87-100.

51. Liu Y, Zou R, Wang Z, Wen C, Zhang F, Lin F. Exosomal KLF3-AS1 from hMSCs promoted cartilage repair and chondrocyte proliferation in osteoarthritis. Int J Mol Sci. 2018; 19(47):2369-3638.

52. Zhu Y, Wang Y, Zhao B, Niu X, Hu B, Li Q, Zhang J, Ding J, Chen Y, Wang Y. Comparison of exosomes secreted by induced pluripotent stem cell-derived mesenchymal stem cells and synovial membrane-derived mesenchymal stem cells for the treatment of osteoarthritis. Stem Cell Res Ther. 2017; 8(1):64.

53. Chen Y, Xue K, Zhang X, Zheng Z, Liu K. Exosomes derived from mature chondrocytes facilitate subcutaneous stable ectopic chondrogenesis of cartilage progenitor cells. Stem Cell Res Ther. 2018;9(1):318.

54. Liu Y, Lin L, Zou R, Wen C, Wang Z, Lin F. MSC-derived exosomes promote proliferation and inhibit apoptosis of chondrocytes via IncRNA-KLFO3-AS1/miR-206/GIT1 axis in osteoarthritis. Cell Cycle. 2018; 17(22):2411-2422.

55. Tao SC, Yuazheng Z, Lin Y, Wu SC, Zhao SC, Zhang Q. Exosomes derived from miR-148a-3p-overexpressing human synovial mesenchymal stem cells enhance cartilage tissue regeneration and prevent osteoarthritis in the knee of a rat model. Theranostics. 2017;7(1):180-195.

56. Sun H, Hu S, Zhang Z, Luo J, Liao W, Zhang Z. Expression of exosomal miR-376a-3p during chondrogenic differentiation of human bone mesenchymal stem cells. J Cell Biochem. 2019; 120(1):171-181.

57. Wang R, Xu B, Xu H. TGF-β1 promoted chondrocyte proliferation by regulating Sp1 through MSC-exosomes derived miR-135b. Cell Cycle. 2018; 17(18):2574.

58. Bissell MJ, Hines WC. Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med. 2011; 17(3):320-9.

59. Lucchetti D, Calapà F, Palmieri V, Fanali C, Carbone F, Papa A, De Maria R1, 17(3):320-9.

60. Rocha S, Carvalho J, Oliveira P, Voglstaetter M, Schvartz D, Thomsen AR, Walter N, Khanduri R, Sanchez JC, Lucchetti D, Calapà F, Palmieri V, Fanali C, Carbone F, Papa A, De Maria R1, 17(3):320-9.

61. Han C, Zhou J, Liu B, Pan X, Zhang Y, Wang Y, Yan B, Xie W, Liu F, Yu XY, Li Y. Human umbilical cord mesenchymal stem cell derived exosomes encapsulated in functional peptide hydrogels promote cardiac repair. Biomater Sci. 2019; 7(7): 2917-3010.

62. Zhang Y, Chopp M, Zhang ZG, Katakowski M, Xin H, Qu C, Ali M, Mahmood A, Xiong Y. Systemic administration of cell-free exosomes generated by bone marrow stromal cells improves cardiac function by regulating Sp1 through MSC-exosomes derived miR-135b. Cell Cycle. 2018; 17(24).

63. Shinomura M, Okamura H, Takigawa M, Nakatsura T, Kozaki KI, Okamoto K, Amnion-Derived Mesenchymal Stem Cells between 2D and 3D Culture Increases Exosome Secretion from Mesenchymal Stem Cells. Tissue Eng A. 2019;25(9-10):1547-1559.

64. Kim M, Yun HW, Park DY, Choi BH, Min BH. Three-Dimensional Spheroïd Culture Increases Exosome Secretion from Mesenchymal Stem Cells. Tissue Eng Regen Med. 2018; 15(4):427-436.

65. Mironov Y, Pampalone M, Vella S, Carroca AP, Amico G, Conaldi PG. Comparison of Immunopressorvive and Angiogenic Properties of Human Amnion-Derived Mesenchymal Stem Cells between 2D and 3D Culture Systems. Stem Cells Int. 2019;2019:7486279.

66. Liu X, Yang Y, Li Y, Niu X, Zhao B, Wang Y, Bao C, Xie Z, Lin Q, Zhu L. Integration of stem cell-derived exosomes with in situ hydrogel glue as a promising tissue patch for articular cartilage regeneration. Nanoscale. 2017, 9(13): 4430-4438.

67. Diomede F, Gugliandolo A, Cardelli P, Merciario I, Ettore E, Tettari T, Bedini R, Sciorti D, Bramanti A, Nanci A, Caputi S, Fontana A, Mazzon E, Trubiani O. Three-dimensional printed PLA scaffold and human gingival stem cell-derived extracellular vesicles: a new tool for bone defect repair. Stem Cell Res Ther. 2018; 9(1):104.

68. Pizzica-Gazzanella J, Diomede F, Gugliandolo A, Chiricosta L, Bramanti P, Merciario I, Orsini T, Mazzon E, Trubiani O. 3D Printing PLA/Gingival Stem Cells/ EVs Upregulated miR-2861 and -210 during Osteoangiogenesis Commitment. Int J Mol Sci. 2019;20(13). pii: E3256.

69. Chen P, Zheng L, Wang Y, Tao M, Xie Z, Xie C, Gu C, Chen J, Qiu P, Mei S, Ning L, Shi Y, Fang C, Fan S, Lin X. Desktop-stereolithography 3D printing of a radially oriented extracellular matrix/mesenchymal stem cell exosome biotak for osteochondral defect regeneration. Theranostics. 2019; 9(18):9169-9179.

70. Batagov AO, Kuznetsova VA, Kourochkin IV. Identification of nucleotide patterns enriched in secreted RNAs as putative cis-acting elements targeting them to exosome nano-vesicles. BMC Genomics. 2011;12:Suppl 3:S38.